Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives

International Journal of Pharmaceutics

Volumn 399, Issue 1-2, 2010, Pages 129-139

  Shegokar, Ranjita ^a   Müller, Rainer H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Bioavailability enhancement; High pressure homogenization; Nanocrystals; Poor solubility; SmartCrystals; Solubilization; Targeting

Indexed keywords

2 METHOXYESTRADIOL; APREPITANT; BEVACIZUMAB; BRAIN PROTEIN; BUDESONIDE; BUSULFAN; CALCIUM PHOSPHATE; COSMETIC; DEXMETHYLPHENIDATE; FENOFIBRATE; INSULIN; MEGACE ES; MEGESTROL ACETATE; METHYLPHENIDATE; MORPHINE SULFATE; NANOCRYSTAL; NUCRYST; NUTRACEUTICAL; PACLITAXEL; RAPAMYCIN; SEMAPIMOD; THERALUX; TIZANIDINE; TRIGLIDE; UNCLASSIFIED DRUG;

CAPSULE ENDOSCOPE; DRUG FORMULATION; DRUG MARKETING; FEASIBILITY STUDY; NANOTOXICOLOGY; NUTRITION; PRIORITY JOURNAL; REVIEW; TABLET;

ADMINISTRATION, ORAL; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; INJECTIONS, INTRAVENOUS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 77956882799     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.044     Document Type: Review

References (79)

1. Al Shaal, L., Shegokar, R., Müller, R.H., 2010a. Apigenin smartCrystals for novel UV skin protection formulations. Eighth European Workshop on Particulate Systems Abstract no. 22.
2. Al Shaal, L., Shegokar, R., Müller, R.H., Keck, C.M., 2010b. Novel UV skin protective antioxidant nanocrystals. First Combined Annual Meeting of the International Pharmaceutical Federation, PSWC and AAPS. Abstract No. 2221.
3. Araújo J., Gonzalez E., Egea M.A., Garcia M.L., Souto E.B. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomed.: Nanotechnol., Biol. Med. 2009, 5:394-401.
4. Arunkumar N., Deecaraman M., Rani C. Nanosuspension technology and its applications in drug delivery. Asian J. Pharm. 2009, 3:168-173.
5. Auweter H., Andre V., Horn D., Luddecke E. The function of gelatin in controlled precipitation processes of nanosize particles. J. Dispersion Sci. Technol. 1998, 163-184.
6. Auweter, H., Bohn, H., Heger, R., Horn, D., Siegel, B., Siemensmeyer, K., 2002. Precipitated water-insoluble colorants in colloid disperse form, in US Patent 6,494,924. BASF AG.
7. Blunk T., Hochstrasser D.F., Sanchez J.C., Müller B.W., Müller R.H. Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1993, 14:1382-1387.
8. Böhm, B.H.L., 1999. Herstellung und Charakterisierung von Nanosuspensionen als neue Arzneiform für Arzneistoffe mit geringer Bioverfügbarkeit. Ph.D. Thesis, Freie Universität Berlin, Germany.
9. Bucolo C., Maltese A., Puglisi G., Pignatello R. Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspension. Ophthalmic Res. 2002, 34:319-323.
10. Chiang P.C., Hu Y., Thurston A., Sommers C.D., Guzova J.A., Kahn L.E., Lai Y., Blom J.D. Pharmacokinetic and pharmacodynamic evaluation of the suitability of using fluticasone and an acute rat lung inflammation model to differentiate lung versus systemic efficacy. J. Pharm. Sci. 2009, 98:4354-4364.
11. Chow, D.S.L., Gupta, P., Qi, Y., Liang, D., Shah, J., Wisniecki, P., 2010. Parenteral and Oral Formulations of Benzimidazoles. WO/2010/011289.
12. Crisp M.T., Tucker C.J., Rogers T.L., Williams R.O., Johnston K.P. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J. Controlled Release 2007, 117:351-359.
13. Dandagi P., Kerur S., Mastiholimath V., Gadad A., Kulkarni A. Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution. Iranian J. Pharm. Res. 2009, 8:79-86.
14. de Waard H., Hinrichs W.L., Frijlink H.W. A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying. J. Controlled Release 2008, 128:179-183.
15. de Waard H., Grasmeijer N., Hinrichs W.L., Eissens A.C., Pfaffenbach P.P., Frijlink H.W. Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large scale production. Eur. J. Pharm. Sci. 2009, 38:224-229.
16. Deng J., Huang L., Liu F. Understanding the structure and stability of paclitaxel nanocrystals. Int. J. Pharm. 2010, 390:242-249.
17. Diederichs J.E., Müller R.H. Liposome in Kosmetika und Arzneimitteln. Pharm. Ind. 1994, 56:267-275.
18. Friedrich I., Müller-Goymann C.C. Characterization of solidified reverse micellar solutions (SRMS) and production development of SRMS-based nanosuspensions. Eur. J. Pharm. Biopharm. 2003, 56:111-119.
19. Ganta S., Paxton J.W., Baguley B.C., Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int. J. Pharm. 2009, 367:179-186.
20. Gao L., Zhang D., Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res. 2008, 10:845-862.
21. Gao L., Zhang D., Chen M., Duan C., Dai W., Jia L., Zhao W. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int. J. Pharm. 2008, 355:321-327.
22. Ghosh S., Chiang P.C., Wahlstrom J.L., Fujiwara H., Selbo J.G., Roberds S.L. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin. Pharmacol. Toxicol. 2008, 102:453-458.
23. Haynes, D.H., 1992. Phospholipid-coated microcrystals: injectable formulations of water insoluble drugs. US Patent 5091187.
24. Heimbach, T., Fleisher, D., Kaddoumi, A., 2007. Overcoming poor aqueous solubility of drugs for oral delivery. In: Stella, V.J., R.T.B., Hageman, M.J., Oliyai, R., Maag. H., Tilley, J.W. (Eds.), Prodrugs, Series - Biotechnology: Pharmaceutical Aspects Springer, New York, pp. 157-215.
25. Hernandez-Trejo N., Kayser O., Steckel H., Müller R.H. Characterization of nebulized buparvaquone nanosuspensions-effect of nebulization technology. J. Drug Target. 2005, 13:499-507.
26. Hernandez-Trejo, N., 2006. Development and characterisation of buparvaquone nanosuspensions for pulmonary delivery in the treatment of Pneumocystis pneumonia. Ph.D. Thesis, Freie Universität Berlin, Germany.
27. Holsapple M.P., Farland W.H., Landry T.D., Monteiro-Riviere N.A., Carter J.M., Walker N.J., Thomas K.V. Research strategies for safety evaluation of nanomaterials, Part II: toxicological and safety evaluation of nanomaterials, current challenges and data needs. Toxicol. Sci. 2005, 88:12-17.
28. Irizarry L.D., Luu T.H., McKoy J.M., Samaras A.T., Fisher M.J., Carias E.E., Raisch D.W., Calhoun E.A., Bennett C.L. Cremophor EL-containing paclitaxel induced anaphylaxis: a call to action. Community Oncol. 2009, 6:132-134.
29. Kassem M.A., Abdel Rahman A.A., Ghorab M.M., Ahmed M.B., Khalil R.M. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 2007, 340:126-133.
30. Kayser O. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int. J. Pharm. 2001, 214:83-85.
31. Kayser O., Olbrich C., Yardley V., Kiderlen A.F., Croft S.L. Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 2003, 254:73-75.
32. Keck C.M., Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 2006, 62:3-16.
33. Keck C.M., Kobierski S., Mauludin R., Müller R.H. Second generation of drug nanocrystals for delivery of poorly soluble drugs: smartCrystal technology. Dosis 2008, 2:124-128.
34. Kipp, J.E.W., Joseph, C.T., Doty, M.J., Rebbeck, C.L., 2001. Microprecipitation method for preparing submicron suspensions. US Patent 6869617.
35. Kislalioglu M.S. Cosmetic regulations of the United States, European Union, and Japan. Clin. Res. Regul. Affairs 1996, 13:211-229.
36. Kohno S., Otsubo T., Tanaka E., Maruyama K., Hara K. Amphotericin B encapsulated in polyethylene glycolimmunoliposomes for infectious diseases. Adv. Drug Del. Rev. 1997, 24:325-329.
37. Kreuter J., Petrov V.E., Kharkevich D.A., Alyautdin R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Controlled Release 1997, 49:81-87.
38. List, M., Sucker, H., 1988. Pharmaceutical colloidal hydrosols for injection. GB Patent 2200048.
39. Liversidge G.G., Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 1995, 125:91-97.
40. Liversidge, G.G., Cundy, K.C., Bishop, J., Czekai, D., 1992. Surface modified drug nanoparticles. US Patent 5145684.
41. Lück M., 1997. Plasmaproteinadsorption als ein möglicher Schlüsselfaktor für eine kontrollierte Arzneistoffappliktion mit partikulären Trägern. Ph.D. Thesis, Freie Universität Berlin.
42. Mauludin, R., 2008. Nanosuspensions of poorly soluble drugs for oral administration. Ph.D. Thesis, Freie Universität Berlin, Germany.
43. Mauludin R., Müller R.H., Keck C.M. Development of an oral rutin nanocrystal formulation. Int. J. Pharm. 2009, 370:202-209.
44. Merisko-Liversidge E.M., Liversidge G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 2008, 36:43-48.
45. Merisko-Liversidge E., Liversidge G.G., Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18:113-120.
46. Möschwitzer J., Müller R.H. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur. J. Pharm. Biopharm. 2006, 62:282-287.
47. Müller R.H., Akkar A. Drug nanocrystals of poorly soluble drugs. Encyclopedia of Nanoscience and Nanotechnology 2004, 627-638. American Scientific Publishers. H.S. Nalwa (Ed.).
48. Müller, R.H., Becker, R., Kruss, K.P., 1992. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. US Patent 5858410.
49. Müller, R.H., Becker, R., Kruss, B., Peters, K., 1999. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. US Patent 5858410.
50. Müller R.H., Böhm B.H.L., Grau M.J. Nanosuspensions-a formulation approach for poorly soluble and poorly bioavailable drugs. Handbook of Pharmaceutical Controlled Release 2000, 345-357. Marcel Dekker, New York. D.L. Wise (Ed.).
51. Müller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv. Drug Del. Rev. 2001, 47:3-19.
52. Müller, R.H., Krause, K., Mäder, K., 2001b. Method for controlled production of ultrafine microparticles and nanoparticles. WO/2001/003670.
53. Müller R.H., Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int. J. Pharm. 2002, 237:151-161.
54. Müller, R.H., Pardeike, J., Hommoss, A., 2006. Nanoparticles in therapeutics: drug nanocrystals and lipid nanoparticles. NanoTrends, Potsdam, Germany.
55. Müller, R.H., Shegokar, R., Singh, K.K., 2009. Positively charged nanostructured lipid carriers (NLC) for drug delivery by adhesion. Ninth International Symposium on 'Advances in Technology and Business Potential of New Drug Delivery Systems' Controlled Release Society-Indian Local Chapter,Mumbai, India, P36.
56. Noyes A.A., Whitney W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 1897, 19:930-934.
57. Pandey S. Itraconazole nanosuspension meant for oral use: development of formulation, characterization and in vitro comparison with some marketed formulations. Der Pharmacia Lettre 2010, 2:162-171.
58. Peters K., Leitzke S., Diederichs J.E., Borner K., Hahn H., Müller R.H., Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection. J. Antimicrob. Chemother. 2000, 45:77-83.
59. Petersen, R., 2006. Nanocrystals for use in topical cosmetic formulations and method of production thereof. US Patent 60/8866233.
60. Piao H., Kamiya N., Hirata A., Fujii T., Goto M. A novel solid-in-oil nanosuspension for transdermal delivery of diclofenac sodium. Pharm. Res. 2008, 25:896-901.
61. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug. Discov. 2004, 3:785-796.
62. Rabinow B. Pharmacokinetics of drugs administered in nanosuspension. Discovery Med. 2005, 5:74-79.
63. Rabinow B., Kipp J., Papadopoulos P., Wong J., Glosson J., Gass J., Sun C.S., Wielgos T., White R., Cook C., Barker K., Wood K. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int. J. Pharm. 2007, 339:251-260.
64. Ravichandran R. In vivo pharmacokinetic studies of albendazole nanoparticulate oral formulations for improved bioavailability. Int. J. Green Nanotechnol.: Biomed. 2010, 2:B46-B53.
65. Schöler N., Krause K., Kayser O., Müller R.H., Borner K., Hahn H., Liesenfeld O. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother. 2001, 45:1771-1779.
66. Shegokar, R., 2010. Development and evaluation of novel drug delivery systems for an anti-HIV Drugs. Ph.D. Thesis, S.N.D.T. Women's University, Mumbai, India.
67. Shegokar, R., Singh, K.K., 2009. Antiretroviral Nanosuspensions for Latent HIV Reservoir Targeting. 36th Annual Meeting and Exposition of the Controlled Release Society, Copenhagen, Denmark., Abstract No. 588.
68. Shegokar R., Singh K.K., Müller R.H., 2009. Targeting to Latent HIV reservoirs: production optimization and evaluation of nevirapine nanosuspensions, 69th International Congress of FIP. Istanbul, Turkey. Abstract No. 451.
69. Shegokar, R., Al Shaal, L., Müller, R.H., Keck, C.M., 2010a. Apeginin nanocrystal for supportive anticancer treatment. Int. J. Pharm., submitted for publication.
70. Shegokar, R., Al Shaal, L., Müller, R.H., 2010b. Local anaesthetic nanocrystal as prologed release formulation. First Combined Annual Meeting of the International Pharmaceutical Federation, PSWC and AAPS New Orleans, Louisiana, USA, Abstract no. 2203.
71. Shegokar, R., Jansch, M., Singh, K.K., Müller, R.H, 2010c. In-vitro protein adsorption studies on nevirapine nanosuspensions for HIV chemotherapy. Nanomed.: Nanotechnol., Biol. Med., submitted for publication.
72. Suker, H., Gassmann, P., 1994. Improvements in pharmaceutical compositions. GB Patent 2269536A.
73. US-FDA. http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/default.htm.
74. Wahlstrom, J.L., Chiang, P.C., Ghosh, S., Warren, C.J., Wene, S.P., Albin, L.A., Smith, M.E., Roberds, S.L., 2007. Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. Nanoscale Res. Lett. 2, 291-296.
75. weblink1, http://www.wissenschaft-technik-ethik.de/wasser_dampfdruck.html.
76. weblink2, http://www.caelo.de/getfile.html%3Ftype=sdb%26num=3274.
77. weblink3, http://www.europarl.europa.eu/sides/getDoc.do%3Ftype=IM-PRESS%26reference=20090323IPR52331%26language=EN.
78. Wolf G.L., Shore M.T., Bessin G., McIntire G.L., Bacon E.R., Illig K.J. Lymph node extraction of radiopaque nanoparticulates in the rabbit as measured in vivo with CT. Acad. Radiol. 1999, 6:55-60.
79. Xiong R., Lu W., Yue P., Xu R., Li J., Chen T., Wang P. Distribution of an intravenous injectable nimodipine nanosuspension in mice. J. Pharm. Pharmacol. 2008, 60:1155-1159.